Visser, L.E.Kyei-Faried, S.Belcher, D.W.Geelhoed, D.W.Van Leeuwen, J.S.Van Roosmalen, J.2019-04-112019-04-112008-05https://doi.org/10.1016/j.trstmh.2007.11.006Volume 102, Issue 5, Pages 445-450http://ugspace.ug.edu.gh/handle/123456789/29168This study compares two antivenoms used to treat Echis ocellatus snake bite patients at Mathias Hospital, Yeji, central Ghana. FAV-Afrique™ antivenom (Aventis Pasteur) was given to 278 patients during 2001-2003, whilst Asna Antivenom C (Bharat Serum and Vaccines Ltd) was used in 2004 to treat 66 patients. The two groups had comparable patient attributes, time from snake bite to treatment and staff adherence to the tested treatment protocol. The antivenom C group required more repeat doses and twice the amount of antivenom to treat coagulopathy. Of greater concern, the antivenom C mortality rate was 12.1%, a marked rise from the 1.8% rate in the earlier FAV-Afrique™ antivenom group. In this study, antivenom C was ineffective as treatment for West African E. ocellatus snake venom. This illustrates the absolute need for regional pilot tests to assess the effectiveness of a new antivenom against local snake venoms before its sole and general distribution in a region is initiated. © 2007 Royal Society of Tropical Medicine and Hygiene.enAntivenomCarpet viperEnvenomationEvaluationGhanaSnake biteArticle